Cargando…

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers

Resistance of breast cancer to human epidermal growth factor receptor 2 (HER2) inhibitors involves reprogramming of the kinome through HER2/HER3 signaling via the activation of multiple tyrosine kinases and transcriptional upregulation. The heterogeneity of induced kinases prevents kinase targeting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Bowen, Mason, Seth, Wilson, Robert C., Hazard, Starr E., Wang, Yubao, Fang, Rong, Wang, Qiwei, Yeh, Elizabeth S., Yang, Meixiang, Roberts, Thomas M., Zhao, Jean J., Wang, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937212/ https://www.ncbi.nlm.nih.gov/pubmed/31462705 http://dx.doi.org/10.1038/s41388-019-0953-9

Ejemplares similares

The CDK-activating kinase Cdk7: Taking yes for an answer
por: Schachter, Miriam Merzel, et al.
Publicado: (2013)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
por: Hu, Chen, et al.
Publicado: (2023)

Overcoming Resistance to HER2 Inhibitors Through State-Specific Kinase Binding
por: Novotny, Chris J., et al.
Publicado: (2016)

Mms19 is a mitotic gene that permits Cdk7 to be fully active as a Cdk-activating kinase
por: Nag, Rishita Narendra, et al.
Publicado: (2018)

Role of transcription-regulating kinase CDK8 in colon cancer metastasis
por: Liang, Jiaxin, et al.
Publicado: (2019)

Linking cancer transcriptional addictions by CDK7 to YAP/TAZ
por: Piccolo, Stefano
Publicado: (2020)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

Regulatory functions of the Mediator kinases CDK8 and CDK19
por: Fant, Charli B., et al.
Publicado: (2018)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
por: Kwiatkowski, Nicholas, et al.
Publicado: (2014)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
por: Iida, Mari, et al.
Publicado: (2014)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion
por: Zarei, Mahsa, et al.
Publicado: (2019)

Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules
por: Dannappel, Marius Volker, et al.
Publicado: (2019)

Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
por: Lin, Yueh-Te, et al.
Publicado: (2021)

Targeting transcription in heart failure via CDK7/12/13 inhibition
por: Hsu, Austin, et al.
Publicado: (2022)

SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
por: Yoshida, Akihiro, et al.
Publicado: (2019)

Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
por: Ding, Xiaokai, et al.
Publicado: (2022)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
por: Irie, Hiroki, et al.
Publicado: (2020)

CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response
por: Bancerek, Joanna, et al.
Publicado: (2013)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer
por: Zeng, Kaixuan, et al.
Publicado: (2023)

A CDK-related kinase regulates the length and assembly of flagella in Chlamydomonas
por: Tam, Lai-Wa, et al.
Publicado: (2007)

SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription
por: Blank, Maximilian F., et al.
Publicado: (2017)

Cell Cycle-Dependent Transcription: The Cyclin Dependent Kinase Cdk1 Is a Direct Regulator of Basal Transcription Machineries
por: Enserink, Jorrit M., et al.
Publicado: (2022)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
por: Colleoni, B, et al.
Publicado: (2017)

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia
por: Yeh, Yuh-Ying, et al.
Publicado: (2014)

Cdk5: An Emerging Kinase in Pain Signaling
por: Pareek, Tej Kumar, et al.
Publicado: (2012)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
por: Schedin, Troy B., et al.
Publicado: (2018)

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Liu, Yunhua, et al.
Publicado: (2018)

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
por: Zeng, Mei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7mbg48bntfkg43k1oacsqtudqr